Battaglia M, et al. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2019 Nov 21. [Epub ahead of print]
It has long been thought that the T1D phenotype results from a single pathogenic mechanism. However, during the last two decades it has become evident that different pathogenic mechanisms can lead to the same phenotype. This also implies that therapies directed to specific pathways will only help a subgroup of patients. This line of reasoning lead to the term “endotype”, to differentiate different pathobiological mechanisms.
The authors argue that T1D clinical trials so far have not accounted for the potential confounding effect of heterogeneity in their study designs, e.g. by stratifying for disease severity, age and genetic predisposition. Even in trials which fail to meet the primary objective(s), often a subgroup of patients responds well to the experimental treatment. For example, in a study on teplizumab (a monoclonal anti-CD3 antibody) the drug failed to meet its primary outcome, but younger patients with higher C-peptide production capacity and those from North America and Europe responded well to the drug. Also subgroups defined based on HLA and ZnT8 seemed to show different responses for this drug. In this context the term “theratype” is coined.
The authors say that
Another important point raised by the authors is that much can be learned from other diseases such as asthma, where the endotype concept has resulted in the development of drugs affecting different pathobiological pathways so that subtypes of the disease can be treated differentially. It should be noted, however, that things are more difficult for T1D. For starters, the pancreas is not as accessible as the lung.
Three approaches for establishing different endotypes are proposed:
It could be envisaged that combinations of therapies will be developed to cover subgroups of patients.
Click here for the Pubmed abstract.